Australia’s Therapeutic Goods Administration (TGA) has updated its guidance on the timeframes for supplying Unique Device Identification (UDI)-compliant medical devices in Australia.
The guidance, originally published in May 2025, was last updated on 12 November 2026 and is intended to help sponsors and manufacturers understand the phased implementation of Australia’s UDI requirements and the applicable transitional arrangements.
Version 2.2 Corrects IVDD-to-IVDR Transitional Dates
The latest update is Version 2.2, dated 12 November 2026.
According to the TGA’s page history, the update was made to:
correct a discrepancy in the EU IVDD to EU IVDR transitional arrangement dates.
This correction is particularly relevant for sponsors and manufacturers relying on European regulatory transitions when determining how existing IVDs are treated under Australia’s UDI implementation framework.
Purpose of the Guidance
The TGA states that the guidance was developed to help sponsors and manufacturers:
understand Australia’s UDI requirements;
identify applicable UDI compliance dates;
interpret the phased implementation approach;
understand transitional arrangements;
apply the requirements through practical examples.
The document focuses specifically on timeframes rather than the full technical requirements for UDI.
Separate Guidance Covers General UDI Requirements
The TGA makes clear that this document does not describe the general UDI requirements for medical devices and IVDs.
For requirements relating to:
labelling;
packaging;
identifiers;
manufacturers and sponsors should consult the separate guidance “Complying with the Unique Device Identification requirements for medical devices.”
The TGA encourages readers to review that document first because it explains terminology and broader UDI obligations not repeated in the timeframe guidance.
Australia’s UDI Legal Framework
The guidance is supported by two key legislative instruments:
Therapeutic Goods Legislation Amendment (Australian Unique Device Identification Database and Other Measures) Regulations 2025;
Therapeutic Goods (Medical Devices) Regulations 2002.
These provide the legal framework underpinning Australia’s UDI implementation.
A Phased UDI Implementation
Australia is implementing UDI through a phased approach rather than requiring all devices to comply at the same time.
The TGA guidance is intended to help organisations determine when specific devices need to meet the applicable requirements and how transitional arrangements affect existing products.
For manufacturers with large portfolios, this makes product-level assessment particularly important.
Previous Update Added Final Consent to Supply Details
The November update follows Version 2.1, issued on 24 June 2026.
That version incorporated:
finalised details of the UDI Consent to Supply process;
new Consent to Supply resources available through the UDI Hub.
This process is relevant where a sponsor seeks permission to supply a device that does not yet fully comply with applicable UDI requirements under the circumstances permitted by the regulatory framework.
Major Clarifications Added in Version 2.0
The earlier Version 2.0, issued on 22 May 2026, introduced several substantial clarifications.
These included:
clarification of existing devices;
clarification of EU MDD-to-MDR transition arrangements;
clarification of EU IVDD-to-IVDR transition arrangements;
additional timeline graphics;
information on consignment stock;
clarification of sponsor control;
a compliance date summary;
information on existing devices in Surgical Loan Kits.
The latest Version 2.2 should therefore be read as a targeted correction to an already substantially expanded guidance document.
Importance for IVD Manufacturers
The correction to EU IVDD-to-IVDR transitional arrangement dates is particularly important for IVD manufacturers.
Companies that use EU regulatory status as part of their Australian transition planning should verify that internal:
regulatory assessments;
UDI implementation plans;
product inventories;
compliance trackers;
transition dates
reflect the corrected TGA information.
Importance for Sponsors
In Australia, sponsors play a central role in ensuring that devices supplied to the market meet applicable regulatory requirements.
The updated guidance means sponsors should review whether products within their portfolios are:
existing devices;
subject to transitional arrangements;
approaching a UDI compliance date;
affected by European MDR or IVDR transition provisions;
potentially eligible for Consent to Supply arrangements.
Avoid Relying on Older Versions
Because Version 2.2 specifically corrects a discrepancy in transitional dates, organisations should avoid relying on previously downloaded versions without checking the current TGA guidance.
The PDF itself also warns that downloaded content may become outdated and recommends referring to the digital version for current information.
UDI Compliance Requires Cross-Functional Coordination
UDI implementation often affects multiple internal functions, including:
regulatory affairs;
quality assurance;
labelling;
packaging;
supply chain;
master data;
IT systems;
commercial operations.
A change to a regulatory transition date can therefore have consequences beyond the regulatory department alone.
Impact on Existing Devices
One of the key themes in the guidance history is clarification of how existing devices are treated.
This is important because the UDI requirements are being implemented progressively, and devices already supplied or already under sponsor control may not always be treated in the same way as newly supplied products.
Organisations should therefore avoid assuming that a single compliance date applies universally across an entire portfolio.
Consignment Stock and Sponsor Control
Version 2.0 also added information relating to consignment stock and clarified the definition of sponsor control.
These concepts can be important when determining whether a particular device falls within a transition or supply scenario.
For companies using complex distribution arrangements, this may require coordination between regulatory, logistics and commercial teams.
Surgical Loan Kits
The TGA also previously added specific information on existing devices in Surgical Loan Kits (SLKs).
This reflects the practical complexity of applying UDI obligations to devices that may circulate between healthcare facilities as part of reusable instrument or implant-support systems.
Practical Actions for Manufacturers and Sponsors
Following the November 2026 update, companies should consider:
confirming that they are working from Version 2.2;
reviewing corrected IVDD-to-IVDR transition dates;
checking affected IVD portfolios;
reconciling Australian UDI timelines with EU transition strategies;
reviewing existing-device classifications;
verifying consignment stock treatment;
reviewing Surgical Loan Kit arrangements;
assessing whether Consent to Supply may be relevant;
updating internal UDI compliance trackers.
Broader Importance of UDI in Australia
Australia’s UDI framework is intended to improve the identification and traceability of medical devices throughout their lifecycle.
A consistent UDI framework can support:
device identification;
supply-chain traceability;
adverse event investigation;
recalls and corrective actions;
post-market surveillance;
healthcare system data quality.
For manufacturers and sponsors, however, implementation requires careful management of both regulatory deadlines and operational data.
Regulatory Monitoring Remains Important
The sequence of updates during 2026 demonstrates that Australia’s UDI implementation guidance continues to evolve.
Version 2.0 introduced major clarifications in May, Version 2.1 added final Consent to Supply information in June, and Version 2.2 corrected transitional arrangement dates in November.
Regulatory teams should therefore continue monitoring the TGA UDI Hub rather than treating implementation planning as static.